HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies.
Antibodies that cross-react with multiple HIV-1 envelopes (Envs) are useful reagents for characterizing Env proteins and for soluble Env capture and purification assays. We previously reported 10 murine monoclonal antibodies induced by group M consensus Env, CON-6 immunization. Each demonstrated broad cross-reactivity to recombinant Envs. Here we characterized the Env epitopes to which they bind. Seven mapped to linear epitopes in gp120, five at the Env N-terminus, and two at the Env C-terminus. One antibody, 13D7, bound at the gp120 N-terminus (aa 30-42), reacted with HIV-1-infected CD4+T cells, and when expressed in a human IgG1 backbone, mediated antibody-dependent cellular cytotoxicity. Antibody 18F11 bound at the gp120 C-terminus (aa 445-459) and reactivity was glycan dependent. Antibodies 13D7, 3B3, and 16H3 bound to 100 percent of HIV-1 Envs tested in ELISA and sodium dodecyl sulfate/polyacrylamide gel electrophoresis/western blot analysis. These data define the epitopes of monoclonal antibody reagents for characterization of recombinant Envs, one epitope of which is also expressed on the surface of HIV-1-infected CD4+T cells.
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.|2 Department of Immunology, Duke University School of Medicine , Durham, North Carolina.
R Ryan
RR
Meyerhoff
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.
Richard M
RM
Scearce
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.
Damon F
DF
Ogburn
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.
Brad
B
Lockwood
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.|3 Department of Surgery, Duke University School of Medicine , Durham, North Carolina.
Joy
J
Pickeral
2 Department of Immunology, Duke University School of Medicine , Durham, North Carolina.
Masa
M
Kuraoka
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.
Kara
K
Anasti
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.
Joshua
J
Eudailey
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.
Amanda
A
Eaton
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.
Melissa
M
Cooper
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.
Kevin
K
Wiehe
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.|3 Department of Surgery, Duke University School of Medicine , Durham, North Carolina.
David C
DC
Montefiori
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.|3 Department of Surgery, Duke University School of Medicine , Durham, North Carolina.
Georgia
G
Tomaras
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.|3 Department of Surgery, Duke University School of Medicine , Durham, North Carolina.
Guido
G
Ferrari
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.
S Munir
SM
Alam
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.|4 College of Life Science and Technology, Jinan University , Guangzhou, China .
Hua-Xin
HX
Liao
5 Los Alamos National Laboratory , Los Alamos, New Mexico .
Bette
B
Korber
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.
Feng
F
Gao
1 Duke Human Vaccine Institute, Duke University School of Medicine , Durham, North Carolina.|2 Department of Immunology, Duke University School of Medicine , Durham, North Carolina.|6 Department of Medicine, Duke University School of Medicine , Durham, North Carolina.
Barton F
BF
Haynes
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000302:isolation & purification; D000920:Antibody-Dependent Cell Cytotoxicity; D016384:Consensus Sequence; D018604:Epitope Mapping; D000939:Epitopes / Q000235:genetics / Q000276:immunology*; D015483:HIV Antibodies / Q000276:immunology* / Q000302:isolation & purification; D015497:HIV-1 / Q000276:immunology*; D008807:Mice, Inbred BALB C; D054299:env Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*
D016915:AIDS Vaccines; D000911:Antibodies, Monoclonal; D000939:Epitopes; D015483:HIV Antibodies; D054299:env Gene Products, Human Immunodeficiency Virus
ADCC; HIV; antibody-mediated immunity; monoclonal; vaccine design